ES | EN
A doctor and a nurse reviewing a patient's medical records together

How to Request a Genetic Test

We're here to guide you every step of the way—from choosing the test to interpreting the results—with the support of our team of geneticists and a certified laboratory.

From the Clinical Case to the Genetic Diagnosis

A simple process for healthcare professionals, with a leading geneticist who guides you every step of the way.

  1. 1

    Inquiry

    Our geneticists will help you choose the most appropriate test for each patient.

  2. 2

    Application

    Online via Genome Lab at
    or using the application form, along with the informed consent form.

    Download sheet
  3. 3

    Sample

    Sample shipping at no additional cost from your facility.

  4. 4

    Report

    Results report interpreted
    by our geneticists.

Dr. Leyre Larzabal, Head of Clinical Genetics at Dreamgenics
Dr. Leyre LarzabalHead of Clinical GeneticsLicense No.: 1992

Genetic counselling

Dr. Leyre Larzabal will guide you through every stage of the process. She will work with you to determine whether the test is appropriate, interpret the results within their clinical and family context, and advise you on the next steps.

Training
Ph.D. in Biology from the University of Navarra; Bachelor's degrees in Biology and Biochemistry
Accreditation
Public Health Biologist certified by the General Council of Official Associations of Biologists
Experience
More than 10 years of experience in genetic diagnostics and high-throughput sequencing
Companies
Member of the Spanish Association of Human Genetics (AEGH) and the European Society of Human Genetics (ESHG)

What We Need

Three steps to get started with the test, which you can complete online at Genome Lab or on paper. If you have any questions about the sample or the test, please contact us before sending it in.

Application form

Patient and referring physician information, requested test, and clinical information: reason for the visit, phenotype, and family history.

Informed Consent

Signed by the patient or his or her legal representative, as indicated on the application form.

Sample

Peripheral blood in EDTA, saliva, or extracted DNA. Ship at room temperature or refrigerated, at no additional cost from your facility.

Online Application with Genome Lab

Submit the request, attach the clinical information and the informed consent form, and check the status
for each study from our platform, which complies with the GDPR and the standard ISO/IEC 27001:2022.

Go to Genome Lab →

Report of results

A clear and comprehensive clinical report, with the findings highlighted at the beginning and all supporting evidence included. It is signed by licensed clinical geneticists who are members of the AEGH.

  • BackgroundClinical suspicion and reason for the study.
  • ResultKey finding highlighted at the beginning of the report.
  • Identified VariantsGene, zygosity, and allele frequency; RefSeq transcript; HGVS nomenclature; dbSNP ID; and ACMG classification.
  • InterpretationEvidence for each variant in clinical and population databases, in silico prediction and the literature, and CNV analysis.
  • RecommendationsDescription of the disease, segregation studies, reproductive risk, and family history.
  • Secondary FindingsACMG-actionable variants, only with informed consent.
  • AppendicesACMG criteria applied to each variant, depth and coverage, genes analyzed along with their transcripts, methodology, limitations, and references.
Genetic Study of Retinitis Pigmentosa
Code
DG_13.003 | DG Retinitis Pigmentosa
Sample
EDTA Blood
Service
Ophthalmology
Optional
Dr. XX
Result
A likely pathogenic variant and another variant that is pathogenic in heterozygosity have been identified in the CNGB1 gene, associated with autosomal recessive retinitis pigmentosa type 45.
Identified variants
GenVariantZygosityClassification
CNGB1NM_001297.5c.2957A>Tp.(Asn986Ile) | rs201162411Het (43.6%)Likely pathogenic
CNGB1NM_001297.5c.1613G>Ap.(Trp538*) | rs1258900049Het (40.4%)Pathogenic
Conclusion

Assuming that the variants have been inherited in a trans manner, this result would confirm the clinical diagnosis. Segregation analysis is recommended for both parents.

Average depth 134XCoverage ≥20X 96.7%CNVs analyzed
Validated by licensed clinical geneticists | Members of the AEGH

AEGH: Spanish Association of Human Genetics.

Classification of Variants

We classify each variant according to the recommendations of the American College of Medical Genetics and Genomics (ACMG), incorporating population databases, in silico predictors, and clinical information.

  1. PathogenicCausing disease or associated with an increased risk of developing it.
  2. Probably pathogenicMore than a 90% probability of causing disease.
  3. Uncertain significance (VUS)Insufficient evidence to classify it. It will be reevaluated over time.
  4. Probably benignMost likely has no effect on health.
  5. BenignNo known health effects.

Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–424. doi:10.1038/gim.2015.30

Reanalysis and Reevaluation
of VUS

Our understanding of genetics advances every year: new genes are identified, and new evidence allows us to reclassify variants. That is why a result that is inconclusive today may have an answer tomorrow.

  1. 01

    Evidence Tracking

    We periodically review the scientific literature and clinical and population-based databases.

  2. 02

    Reevaluation at 12 months

    Variants with uncertain significance are reevaluated 12 months after the report is issued, applying the ACMG criteria to the new evidence available.

  3. 03

    Notice to the Physician

    If the classification changes, we issue a new report. If not, we send an email to the requesting physician confirming the review.

  4. 04

    Reanalysis of the data

    Exome data are stored and can be reanalyzed in the event of new symptoms, an expanded study, or a diagnosis in a family member.

Frequently Asked Questions

Who can request a study?

Tests must be ordered by a healthcare professional, who receives the report and interprets it within the patient's clinical context.

How do I know which program to apply for?

Our geneticists will help you choose the most appropriate test based on your phenotype, family history, and clinical suspicion. You can also browse our catalog by specialty or search for a specific gene.

What is the deadline for submitting the report?

It depends on the test. Targeted exome sequencing has a turnaround time of 30 business days, and tests using other molecular techniques take 20 to 30 business days.

How do I send the sample?

We coordinate sample collection at your facility at no additional cost. The sample can be shipped at room temperature or refrigerated, along with the request form and the informed consent form.

What happens if the result includes a variant with an uncertain meaning?

Variants with uncertain significance are reevaluated 12 months after the report is issued. If their classification changes, we issue a new report; if not, we send an email to the requesting physician confirming that the variant has been reviewed and that its classification has not changed.

Can a study that has already been conducted be reanalyzed?

Yes. The exome data are stored and can be reanalyzed if new symptoms appear, if you wish to expand the study to include other genes, or if a family member is diagnosed with an inherited disease.

Shall we talk about your patient?

We'll answer your questions about the most appropriate genetic test or send you a no-obligation quote.

  • Response within 24 business hours
  • Advice from our geneticists on choosing a test
  • Sample shipping at no additional cost from your facility
Thank you. Prototype: The form does not submit data.
Business Communications
Terms of Use and Privacy Policy